Literature DB >> 10607943

Melatonin administration can entrain the free-running circadian system of blind subjects.

S W Lockley1, D J Skene, K James, K Thapan, J Wright, J Arendt.   

Abstract

Although melatonin treatment has been shown to phase shift human circadian rhythms, it still remains ambiguous as to whether exogenous melatonin can entrain a free-running circadian system. We have studied seven blind male subjects with no light perception who exhibited free-running urinary 6-sulphatoxymelatonin (aMT6s) and cortisol rhythms. In a single-blind design, five subjects received placebo or 5 mg melatonin p.o. daily at 2100 h for a full circadian cycle (35-71 days). The remaining two subjects also received melatonin (35-62 days) but not placebo. Urinary aMT6s and cortisol (n=7) and core body temperature (n=1) were used as phase markers to assess the effects of melatonin on the During melatonin treatment, four of the seven free-running subjects exhibited a shortening of their cortisol circadian period (tau). Three of these had taus which were statistically indistinguishable from entrainment. In contrast, the remaining three subjects continued to free-run during the melatonin treatment at a similar tau as prior to and following treatment. The efficacy of melatonin to entrain the free-running cortisol rhythms appeared to be dependent on the circadian phase at which the melatonin treatment commenced. These results show for the first time that daily melatonin administration can entrain free-running circadian rhythms in some blind subjects assessed using reliable physiological markers of the circadian system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10607943     DOI: 10.1677/joe.0.164r001

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  62 in total

1.  Circadian Rhythm Sleep Disorders.

Authors:  Min Ju Kim; Jung Hie Lee; Jeanne F Duffy
Journal:  J Clin Outcomes Manag       Date:  2013-11-01

Review 2.  Circadian system, sleep and endocrinology.

Authors:  Christopher J Morris; Daniel Aeschbach; Frank A J L Scheer
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

3.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

4.  A three pulse phase response curve to three milligrams of melatonin in humans.

Authors:  Helen J Burgess; Victoria L Revell; Charmane I Eastman
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

Review 5.  Chronobiological disorders: current and prevalent conditions.

Authors:  Lia R A Bittencourt; Rogerio Santos-Silva; Marco T de Mello; Monica L Andersen; Sergio Tufik
Journal:  J Occup Rehabil       Date:  2010-03

6.  A mathematical model of the circadian phase-shifting effects of exogenous melatonin.

Authors:  Emily R Breslow; Andrew J K Phillips; Jean M Huang; Melissa A St Hilaire; Elizabeth B Klerman
Journal:  J Biol Rhythms       Date:  2013-02       Impact factor: 3.182

7.  Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors.

Authors:  Shadab Ataur Rahman; Shai Marcu; Leonid Kayumov; Colin Michael Shapiro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-12-18       Impact factor: 5.270

Review 8.  Circadian misalignment in mood disturbances.

Authors:  Alfred J Lewy
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

9.  A Pre-Screening Questionnaire to Predict Non-24-Hour Sleep-Wake Rhythm Disorder (N24HSWD) among the Blind.

Authors:  Erin E Flynn-Evans; Steven W Lockley
Journal:  J Clin Sleep Med       Date:  2016-05-15       Impact factor: 4.062

10.  A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.

Authors:  Clifford Singer; Rochelle E Tractenberg; Jeffrey Kaye; Kim Schafer; Anthony Gamst; Michael Grundman; Ronald Thomas; Leon J Thal
Journal:  Sleep       Date:  2003-11-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.